Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.
Scientific reports November 14, 2024 Erin Wang, David S Mathai, Natalie Gukasyan et al. 18 citations
Among 879 U.S. healthcare professionals surveyed online, most endorsed strong belief in the therapeutic promise of psychedelic-assisted therapy with psilocybin and MDMA, and showed moderate openness to clinical use and support for legal access, with higher ratings for psilocybin than MDMA. However, objective knowledge of therapeutic uses, risks, and pharmacology was low. Primary concerns included lack of trained providers, financial cost, and potential contraindications. Prior psychedelic use, self-rated knowledge, younger age, and professional role predicted greater openness, while physicians reported lower openness. Results indicate a pressing need for formal training to provide balanced, evidence-based information.